Jefferies Financial Group’s Alnylam Pharmaceuticals ALNY Stock Holding History

Jefferies Financial Group’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-19,800	Closed	-$4.81M	–	1414
2024 Q2	$4.81M	Buy	19,800 +4,800	+32%	+$758K	0.05%	303
2024 Q1	$2.24M	Buy	15,000 +12,500	+500%	+$2.09M	0.02%	551
2023 Q4	$479K	Hold	2,500	–	–	﹤0.01%	1242
2023 Q3	$443K	Hold	2,500	–	–	﹤0.01%	1114
2023 Q2	$475K	Hold	2,500	–	–	﹤0.01%	1192
2023 Q1	$501K	Sell	2,500 -21,700	-90%	-$4.56M	﹤0.01%	1089
2022 Q4	$5.75M	Buy	+24,200	New	+$5.16M	0.04%	364

Other funds holding ALNY

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Jefferies Financial Group's ALNY Position: Q1 2026 in Review

Jefferies Financial Group reduced its Alnylam Pharmaceuticals (ALNY) stake by 2.9% in Q1 2026, selling an estimated $262K and leaving 25,553 shares worth $8.45M. The position accounts for 0.06% of the portfolio, ranked #232.

Jefferies Financial Group first reported a position in ALNY in Q4 2022 and has held it in 13 quarters since. The position peaked at $13M in Q3 2024. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

Jefferies Financial Group held 25,553 shares of Alnylam Pharmaceuticals worth $8.45M as of Q1 2026.
Jefferies Financial Group sold 769 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $262K.
Alnylam Pharmaceuticals made up 0.06% of Jefferies Financial Group's portfolio in Q1 2026, its #232 holding.
Jefferies Financial Group first reported a position in Alnylam Pharmaceuticals in Q4 2022 and has held it in 13 quarters since.
Jefferies Financial Group's Alnylam Pharmaceuticals position peaked at $13M in Q3 2024.
787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Jefferies Financial Group's 13F filing for Q1 2026, filed 8 May 2026.